Adaptive Immunity in Neurodegeneration

Adaptive Immunity in Neurodegeneration

NeuroWiki - A Mechanistic Knowledge Base for Neurodegenerative Diseases

Introduction

Adaptive Immunity in Neurodegeneration refers to the antigen-specific immune responses mediated by T lymphocytes and B lymphocytes that contribute to, or attempt to counteract, neurodegenerative processes in the central nervous system (CNS). While innate immune responses (microglia, astrocytes) have long been recognized as players in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS), the role of adaptive immunity—comprising T cells, B cells, and major histocompatibility complex (MHC) molecules—has emerged as a critical component in disease pathogenesis and progression.

1. Overview of Adaptive Immunity in the CNS

1.1 Historical Context: Immune Privilege and Its Modern Reinterpretation

The CNS was historically considered an "immune-privileged" site, shielded from the robust immune surveillance that characterizes peripheral tissues. This concept stemmed from the absence of classical lymphatic drainage, the tight encapsulation provided by the blood-brain barrier (BBB), and the low baseline expression of MHC molecules within the neural parenchyma. However, this paradigm has been substantially revised over the past two decades.

Adaptive Immunity in Neurodegeneration

NeuroWiki - A Mechanistic Knowledge Base for Neurodegenerative Diseases

Introduction

Adaptive Immunity in Neurodegeneration refers to the antigen-specific immune responses mediated by T lymphocytes and B lymphocytes that contribute to, or attempt to counteract, neurodegenerative processes in the central nervous system (CNS). While innate immune responses (microglia, astrocytes) have long been recognized as players in neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS), the role of adaptive immunity—comprising T cells, B cells, and major histocompatibility complex (MHC) molecules—has emerged as a critical component in disease pathogenesis and progression.

1. Overview of Adaptive Immunity in the CNS

1.1 Historical Context: Immune Privilege and Its Modern Reinterpretation

The CNS was historically considered an "immune-privileged" site, shielded from the robust immune surveillance that characterizes peripheral tissues. This concept stemmed from the absence of classical lymphatic drainage, the tight encapsulation provided by the blood-brain barrier (BBB), and the low baseline expression of MHC molecules within the neural parenchyma. However, this paradigm has been substantially revised over the past two decades.

Seminal discoveries have demonstrated that the CNS maintains sophisticated immune interactions through multiple pathways. The identification of functional meningeal lymphatic vessels draining CSF into the deep cervical lymph nodes established an anatomical basis for CNS immune surveillance[@louveau2015]. Furthermore, the discovery that microglia, astrocytes, and even neurons can express MHC class I and class II molecules under inflammatory conditions revealed that neural cells possess the machinery to participate in adaptive immune responses[@galea2007].

1.2 Cellular Components of CNS Adaptive Immunity

T lymphocytes represent the predominant adaptive immune population in the CNS.

Figure 1: Adaptive immune pathways in neurodegeneration. Peripheral immune activation drives lymphocyte expansion and CNS infiltration via blood-brain barrier breakdown. CD8+ cytotoxic T lymphocytes and CD4+ Th17 cells release pro-inflammatory cytokines (IFN-gamma, TNF-alpha, IL-17A) that synergize to injure neurons directly or via microglial activation. Disease-specific pathways are shown for Alzheimer's disease (Abeta plaques, tau tangles), Parkinson's disease (alpha-synuclein aggregation, substantia nigra loss), and ALS (motor neuron degeneration, TDP-43 pathology). Therapeutic intervention points are shown in green.

--- Under physiological conditions, small numbers of memory T cells traffic through the CNS as part of routine immune surveillance. The T cell compartment includes:

• CD8+ cytotoxic T lymphocytes (CTLs): Capable of recognizing MHC class I-presented antigens and executing direct cytotoxic responses against target cells.
• CD4+ helper T cells: Including Th1, Th2, Th17, and regulatory T cell (Treg) subsets, each with distinct cytokine profiles and functional outcomes.
• gammadelta T cells: A minor subset with innate-like properties, capable of responding rapidly to stress-induced signals without classical antigen presentation.

Major Histocompatibility Complex (MHC) molecules serve as the antigen-presenting machinery enabling T cell recognition. While MHC class I is ubiquitously expressed on virtually all nucleated cells, including neurons under certain conditions, MHC class II expression is typically restricted to professional antigen-presenting cells (APCs) such as microglia, dendritic cells, and macrophages.

2. Neuroinflammation and Immune Activation in AD, PD, and ALS

2.1 Alzheimer's Disease

Alzheimer's disease, characterized by accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, exhibits a prominent neuroinflammatory component. While early research focused on innate microglial activation, evidence for adaptive immune involvement has accumulated substantially.

Post-mortem studies of AD brain tissue reveal CD8+ T cell infiltrates concentrated around Aβ plaques and within the hippocampus, a region critical for memory and particularly vulnerable in AD[@togo2002]. These infiltrating T cells display an activated phenotype (CD69+, CD45RO+) indicative of local antigen-driven expansion. Peripheral blood mononuclear cells from AD patients show altered T cell subsets, including decreased regulatory T cells (Tregs) and increased Th1 and Th17 populations producing pro-inflammatory cytokines[@saresella2009].

B cells and plasma cells are also present in AD brains, with detectable anti-Aβ antibodies in both CNS tissue and cerebrospinal fluid (CSF). The significance of these antibodies remains debated—they may represent a protective humoral response facilitating Aβ clearance, or potentially contribute to immune complex deposition and inflammatory damage[@britschgi2009].

2.2 Parkinson's Disease

Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of Lewy bodies composed primarily of α-synuclein aggregates. Neuroinflammation is a consistent pathological feature, with evidence pointing to both innate and adaptive immune contributions.

Post-mortem PD brain specimens demonstrate CD8+ and CD4+ T cell infiltrates in the substantia nigra and striatum, often in close proximity to remaining dopaminergic neurons[@mcgeer2015]. The antigenic trigger for these infiltrates likely includes α-synuclein itself—specific α-synuclein epitopes have been shown to activate peripheral T cells in PD patients, and T cell responses to α-synuclein correlate with disease progression[@sulzer2017].

Peripheral immune abnormalities in PD include increased CD4+/CD8+ ratio, elevated pro-inflammatory cytokines, and reduced Treg function. Notably, certain PD risk genes implicated by genome-wide association studies (GWAS), including HLA-DR alleles, directly implicate adaptive immune mechanisms[@hamza2010].

2.3 Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) involves progressive loss of upper and lower motor neurons, leading to muscle weakness and fatal respiratory failure. The majority of cases are sporadic, while approximately 5-10% are familial, associated with mutations in genes including SOD1, C9orf72, TDP-43 (TARDBP), and FUS.

Immune activation in ALS encompasses both innate and adaptive compartments. Murine models (SOD1^G93A^) and human studies reveal CD4+ and CD8+ T cell infiltration of the spinal cord, particularly at disease onset and during rapid progression[@chiu2008]. The C9orf72 repeat expansion, the most common genetic cause of ALS and frontotemporal dementia, is associated with inherent immune dysfunction—haploinsufficiency of C9orf72 leads to enhanced pro-inflammatory responses in microglia and macrophages[@orourke2015].

B cell involvement in ALS is evidenced by the presence of autoantibodies in some patients, including antibodies against neurofilaments, GM1 ganglioside, and voltage-gated calcium channels. The clinical significance of these autoantibodies remains unclear, with some studies suggesting association with more rapid progression[@fereshtehnejad2018].

3. T Cell-Mediated Neurodegeneration

3.1 CD8+ Cytotoxic T Lymphocytes

CD8+ cytotoxic T lymphocytes (CTLs) represent a potent effector population capable of directly inducing neuronal death. Their pathogenic mechanisms in neurodegeneration include:

Perforin/Granzyme Pathway: Activated CTLs release perforin, which forms pores in target cell membranes, enabling granzyme entry. Granzyme B and other caspases then initiate apoptosis of the target neuron. This mechanism has been documented in vitro and in animal models of neurodegeneration[@medana2001].

Fas-FasL Interaction: Engagement of Fas (CD95) on target cells by Fas ligand (FasL) expressed on CTLs triggers the extrinsic apoptosis pathway. Neurons express relatively low levels of Fas under physiological conditions, but inflammatory signals upregulate Fas expression, rendering neurons susceptible to CTL-mediated killing[@dittel1999].

IFN-γ Production: CTLs produce interferon-gamma (IFN-γ), a cytokine with direct and indirect neurotoxic effects. IFN-γ activates microglia toward a pro-inflammatory phenotype, induces expression of MHC molecules on neural cells, and can directly impair neuronal function[@neumann1998].

3.2 CD4+ Helper T Cell Subsets

CD4+ helper T cells contribute to neurodegeneration primarily through cytokine-mediated effects and modulation of the local immune environment.

Th1 Cells: Differentiated by IL-12 and IFN-γ, Th1 cells produce IFN-γ, TNF-α, and IL-2. This cytokine profile promotes pro-inflammatory microglial activation and enhances CTL responses. The Th1/Th2 balance has been shown to shift toward Th1 in both AD and PD[@zhang2007].

Th17 Cells: Differentiated by TGF-β and IL-6 or IL-21, Th17 cells produce IL-17A, IL-17F, and IL-22. IL-17A can directly synergize with TNF-α to induce neuronal apoptosis and can activate astrocytes to produce pro-inflammatory mediators. Th17 cells have been specifically implicated in PD pathogenesis, with IL-17A levels elevated in PD CSF and correlates with disease severity[@liu2020].

Treg Dysfunction: Regulatory T cells (Tregs), characterized by FoxP3 expression, normally function to suppress immune responses. In neurodegenerative diseases, Treg numbers and function are frequently compromised. Treg deficiency in murine models accelerates neurodegeneration, while Treg augmentation through pharmacological or genetic approaches is protective[@reynolds2007].

4. B Cell and Antibody Responses in Neurodegeneration

4.1 Intrathecal Antibody Production

B cells infiltrating the CNS can undergo antigen-driven clonal expansion and differentiate into plasma cells capable of producing antibodies locally. This "intrathecal" antibody production has been documented in all major neurodegenerative diseases.

In AD, IgG antibodies against Aβ have been detected in brain tissue and CSF. Interestingly, some studies suggest that naturally occurring anti-Aβ antibodies may play a protective role by facilitating microglial phagocytosis of Aβ, while others indicate that immune complex formation may exacerbate inflammation[@morgan2015].

4.2 Autoantibodies and Their Significance

The presence of various autoantibodies in neurodegenerative disease patients has been extensively documented:

• Anti-neurofilament antibodies: Detected in PD, ALS, and AD; may reflect neuronal damage and exposure of intracellular antigens.
• Anti-α-synuclein antibodies: Found in PD and multiple system atrophy; target either monomeric or aggregated forms.
• Anti-tau antibodies: Present in AD; specific for various phosphorylated tau epitopes.

4.3 B Cell Depletion Effects

The effects of B cell depletion therapies provide insight into B cell roles in neurodegeneration. Anti-CD20 rituximab has been trialed in some neurodegenerative conditions, though primarily in contexts with prominent B cell involvement (such as some autoimmune encephalitis mimics). In ALS, a trial of rituximab showed minimal effect on disease progression, suggesting B cells may not be primary drivers[@meoli2008].

5. The Role of MHC Molecules and Antigen Presentation

5.1 MHC Class I Expression in the CNS

Under physiological conditions, neurons express low levels of MHC class I, rendering them relatively protected from CTL-mediated destruction. However, this protection can be circumvented by inflammatory signals.

IFN-γ Induction: Pro-inflammatory cytokines, particularly IFN-γ, potently upregulate MHC class I expression on neurons. In vitro, IFN-γ treatment renders neurons susceptible to CTL-mediated killing that is otherwise ineffective[@neumann1999].

Stress-Induced Ligands: NKG2D ligands (MICA, MICB in humans; Rae-1, MULT-1 in mice) are induced on stressed or damaged cells. Engagement of NGR2D on CTLs provides co-stimulatory signals that lower the threshold for cytotoxic activation.

5.2 MHC Class II and Antigen-Presenting Cells

MHC class II expression is essential for CD4+ T cell activation. In the CNS, microglia are the primary professional APCs, though astrocytes and perivascular macrophages can also express MHC class II under inflammatory conditions.

The efficiency of CNS antigen presentation has therapeutic implications. Successful CNS-targeted vaccination requires antigens to be effectively captured, processed, and presented via MHC molecules to stimulate protective T cell responses. Conversely, dysregulated antigen presentation may drive pathogenic autoimmune responses against neural antigens.

5.3 HLA Genetic Associations

GWAS have identified HLA associations with neurodegenerative diseases, providing genetic evidence for antigen presentation involvement:

• Parkinson's disease: HLA-DRB1 alleles influence risk, with specific haplotypes associated with either increased or decreased risk[@hillburns2016].
• ALS: HLA-DRB1 associations have been reported in some populations.
• Alzheimer's disease: Though traditionally associated with APP/PSEN1/PSEN2 genes, HLA associations with risk and age of onset have been reported.

6. Blood-Brain Barrier Dysfunction and Immune Cell Infiltration

6.1 Mechanisms of BBB Breakdown

The blood-brain barrier, composed of tight junction-bearing endothelial cells, pericytes, and astrocyte end-feet, maintains CNS homeostasis by restricting peripheral immune cell entry. BBB dysfunction is a consistent feature of neurodegenerative diseases.

Molecular Mechanisms:

• Matrix metalloproteinases (MMPs): MMP-2 and MMP-9 degrade tight junction proteins (claudin-5, occludin, ZO-1), disrupting barrier integrity. MMP activity is elevated in AD, PD, and ALS[@lorenzl2006].
• Endothelial activation: Pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ) induce expression of adhesion molecules (VCAM-1, ICAM-1) on BBB endothelial cells, facilitating leukocyte adhesion and transmigration.
• Pericyte dysfunction: Pericyte loss or dysfunction compromises barrier integrity and can precede neuronal loss in animal models of neurodegeneration.

6.2 Patterns of Immune Cell Infiltration

The pattern and timing of immune cell infiltration varies among diseases:

• Alzheimer's disease: Early BBB breakdown in hippocampus and cortex; T cell infiltration most prominent around amyloid plaques.
• Parkinson's disease: Leakage of BBB in substantia nigra and striatum; infiltration correlates with disease duration.
• ALS: Prominent early infiltration of T cells in spinal cord; BBB breakdown correlates with disease progression.

6.3 The Neurovascular Unit

The neurovascular unit—a conceptual framework encompassing neurons, astrocytes, pericytes, and endothelial cells—coordinates BBB function and immune privilege. Dysfunction of any component can predispose to pathological immune infiltration. In aging and neurodegenerative disease, cumulative vascular insults (small vessel disease, microinfarcts) compound BBB dysfunction, creating a "perfect storm" for immune cell entry[@zlokovic2011].

7. Therapeutic Implications

7.1 Immunomodulation Strategies

Targeting adaptive immunity in neurodegeneration requires nuanced approaches balancing suppression of pathogenic responses with preservation of protective immunity.

Treg Augmentation: Low-dose IL-2 therapy, already approved for certain autoimmune conditions, has been proposed to expand Tregs in neurodegenerative disease. Preclinical models show promise, with Treg expansion associated with reduced microglial activation and slowed neurodegeneration[@raposo2014].

Th17 Targeting: IL-17A neutralizing antibodies (secukinumab, ixekizumab) are approved for psoriasis and psoriatic arthritis. Repurposing these agents for PD or ALS has been proposed based on preclinical data.

7.2 Intravenous Immunoglobulin (IVIG)

IVIG, a pooled IgG preparation from thousands of donors, exerts immunomodulatory effects through multiple mechanisms:

• Fc receptor modulation: IVIG saturates Fcγ receptors, blocking activation of immune cells.
• Anti-idiotypic antibodies: Neutralizes pathogenic autoantibodies.
• Treg expansion: Promotes Treg development and function.

7.3 Immunosuppressive Approaches

Corticosteroids: Used historically in some neurodegenerative conditions with questionable efficacy. Chronic use is limited by adverse effects and potential worsening of outcomes given the complex immune roles.

Mycophenolate mofetil: Inhibits lymphocyte proliferation by blocking IMP dehydrogenase. Has been trialed in ALS without demonstrated benefit.

Natalizumab: An anti-α4 integrin antibody preventing leukocyte CNS entry. While theoretically attractive for preventing immune infiltration, natalizumab carries significant risks (progressive multifocal leukoencephalopathy) and has not been systematically trialed in neurodegeneration.

7.4 Antigen-Specific Approaches

Aβ Vaccination: The AN1792 active vaccination trial in AD, targeting Aβ, was halted due to meningoencephalitis (likely autoimmune). Subsequent passive immunization approaches with anti-Aβ antibodies continue, with limited success in altering disease trajectory[@van2018].

α-Synuclein Immunization: Active and passive immunization approaches targeting α-synuclein are in development for PD and related synucleinopathies. Early-phase trials have assessed safety and immunogenicity[@volc2020].

8. Key Research Findings

Landmark Studies

1. Meningeal Lymphatic Vessels
> Louveau et al. [Structural and functional features of central nervous system lymphatic vessels](https://pubmed.ncbi.nlm.nih.gov/26030524/). Nature. 2015;523:537-541.
> - Discovered functional lymphatic vessels lining dural sinuses
> - Established anatomical basis for CNS immune surveillance

2. T Cell Surveillance in CNS
> Bartholomäus et al. [T cells in CNS surveillance](https://pubmed.ncbi.nlm.nih.gov/19629042/). Nature. 2009;459:724-734.
> - Demonstrated active T cell patrolling of CNS parenchyma
> - Challenged view of complete immune isolation

3. α-Synuclein T Cell Epitopes
> Sulzer et al. [T cells from patients with Parkinson's disease recognize alpha-synuclein epitopes](https://pubmed.ncbi.nlm.nih.gov/28479331/). Nature. 2017;546:656-661.
> - Identified specific α-synuclein epitopes activating T cells
> - Showed T cell responses correlate with disease progression

4. C9orf72 and Immune Dysfunction
> O'Rourke et al. [C9orf72 deficiency enhances immune activation in a mouse model of ALS](https://pubmed.ncbi.nlm.nih.gov/26581053/). J Exp Med. 2015;212:1875-1893.
> - Demonstrated C9orf72 haploinsufficiency causes immune dysfunction
> - Linked genetic cause to innate and adaptive immune changes

5. Treg in Neurodegeneration
> Reynolds et al. [Regulatory T cells in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/17481545/). J Neurosci. 2007;27:3318-3324.
> - Showed Treg deficiency accelerates neurodegeneration
> - Established therapeutic potential of Treg augmentation

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References